Mizuho raises GRAIL price target to $65, maintains Neutral
Mizuho analyst Bradley Bowers maintains a Neutral rating on GRAIL (NASDAQ: GRAL) and raises the price target from $58 to $65, indicating an updated valuation outlook.
*this image is generated using AI for illustrative purposes only.
Mizuho analyst Bradley Bowers has maintained a Neutral rating on GRAIL (NASDAQ: GRAL) while raising the price target to $65. The adjustment reflects an updated valuation outlook, moving the target up from the previous $58.
The revised price target suggests a specific potential upside based on the company's current market performance. GRAIL operates in the healthcare sector, focusing on early cancer detection.
Rating and Price Action
The following table outlines the rating and price target changes announced by Mizuho:
| Metric | Details |
|---|---|
| Rating | Neutral |
| New Price Target | $65 |
| Previous Price Target | $58 |
The Neutral rating indicates that the analyst expects the stock to perform in line with the broader market or sector averages over the near term.
What specific factors could drive GRAIL's stock to outperform the broader healthcare sector despite the Neutral rating?
How might upcoming clinical trial results impact GRAIL's valuation and future analyst ratings?
What are the potential regulatory hurdles that could affect GRAIL's growth in the early cancer detection market?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
